Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.51 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28313906 | 0.90 | PTGS2 (0.67) | ALOX5PTGS2CYP3A4CNR1CNR2 | |
| SCHEMBL26430138 | 0.89 | PPARA (0.56) | ALOX5CA1CA2CA9FUT7 | |
| SCHEMBL28313908 | 0.89 | PTGS2 (0.65) | ALOX5PTGS2CYP3A4CNR1CNR2 | |
| SCHEMBL10183039 | 0.87 | CYP4F2 (0.58) | ALOX5CYP3A4CYP4F2CYP4A11 | |
| SCHEMBL16952426 | 0.85 | CYP4F2 (0.59) | ALOX5CA1CA2CA9PTGS2 | |
| SCHEMBL16953130 | 0.83 | ALOX5 (0.46) | ALOX5CA1CA2CA9PTGS2 | |
| SCHEMBL30631323 | 0.83 | PPARA (0.63) | CYP3A4PPARGPPARA | |
| SCHEMBL27865972 | 0.83 | PPARA (0.63) | CYP3A4PPARGPPARA | |
| SCHEMBL1517301 | 0.82 | PPARA (0.66) | PPARGPPARACNR1CNR2 | |
| SCHEMBL30375077 | 0.82 | PPARA (0.62) | CYP3A4PPARGPPARACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2404891-B1 | PREPARATION METHOD OF ACYLBENZENES | DSM IP ASSETS BV (NL) | 2015-09-02 | — | — | EP | disclosed |
| US-8642800-B2 | Preparation method of acylbenzenes | DSM IP ASSETS B.V. (NL) | 2014-02-04 | — | — | US | disclosed |
| US-20120022284-A1 | PREPARATION METHOD OF ACYLBENZENES | DSM IP ASSETS B.V. (NL) | 2012-01-26 | — | — | US | disclosed |
| EP-2404891-A1 | PREPARATION METHOD OF ACYLBENZENES | DSM IP Assets B.V. (NL) | 2012-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022284-A1 | PREPARATION METHOD OF ACYLBENZENES | ACACB, SDHB, TET2 | ALOX5 1018/4885CA1 1245/4885CA2 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.